Referenceprogram for angstlidelser hos voksne - Sundhedsstyrelsen

(75) Andersch S, Ottosson J-, Bech P, Hansson L, Lorentzen K, Mellergaard M, et al. Efficacy and
safety of alprazolam, imipramine, and placebo in the treatment of panic disorder. Acta Psychiatr.Scand.
1991;83 (Suppl.365):18-27.
(76) Deltito JA, Argyle N, Klerman GL. Patients with panic disorder unaccompanied by depression
improve with alprazolam and imipramine treatment. J.Clin.Psychiatry 1991;52:121-127.
(77) American Psychiatric Association. Benzodiazepine dependence, toxicity, and abuse. A Task Force
report of the American Psychiatric Association, Washington,DC: American Psychiatric Association.
1990.
(78) Rosenbaum JF, O’Brien CP, Otto MW, Pollack MH, Roy-Byrne PP, Stewart SA.
Benzodiazepines: Revisiting clinical issues in treating anxiety disorders. Prim.Care Companion J.Clin.
Psych. 2005;7(1):23-31.
(79) Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of
clonazepam with sertraline for panic disorder. Arch.Gen.Psychiatry 2001;58(7):681-686.
(80) Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies
of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety,
obsessivecompulsive and posttraumatic stress disorders. World J. Biol.Psychiatry 2002;3(4):171-199.
(81) Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J.Clin.
Psychiatry 2004;65(12):1696-1707.
(82) Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, et al. Efficacy
of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled
study. J.Clin.Psychiatry 2003;64(7):785-792.
(83) Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, et al. Efficacy of Venlafaxine
ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group
comparison with paroxetine. Hum.Psychopharmacol. 2004;19(6):387-396.
(84) Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder:
randomised, placebo-controlled, flexible-dosage study. Br.J.Psychiatry 2005;186:222-226.
(85) Pande AC, Feltner DE, Jefferson JW, Davidson JRT, Pollack M, Stein MB, et al. Efficacy of the
novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J.Clin.
Psychopharmacol. 2004;24(2):141-149.
(86) Blanco C, Schneier FR, Schmidt A, Blanco-Jerez CR, Marshall RD, Sanchez-Lacay A, et al.
Pharmacological treatment of social anxiety disorder: A meta-analysis. Depress. Anxiety 2003;18(1):29-
40.
(87) Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, et al. Efficacy of sertraline
in a 12-week trial for generalized anxiety disorder. Am.J.Psychiatry 2004;161(9):1642-1649.
(88) Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment
of generalized anxiety disorder: a double-blind, placebo-controlled study. Am.J.Psychiatry 2003;
160(4):749-756.
Referenceprogram for angstlidelser hos voksne 12